516 related articles for article (PubMed ID: 16192323)
1. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.
Thoeny HC; De Keyzer F; Vandecaveye V; Chen F; Sun X; Bosmans H; Hermans R; Verbeken EK; Boesch C; Marchal G; Landuyt W; Ni Y
Radiology; 2005 Nov; 237(2):492-9. PubMed ID: 16192323
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
6. Monitoring Vascular Disrupting Therapy in a Rabbit Liver Tumor Model: Relationship between Tumor Perfusion Parameters at IVIM Diffusion-weighted MR Imaging and Those at Dynamic Contrast-enhanced MR Imaging.
Joo I; Lee JM; Grimm R; Han JK; Choi BI
Radiology; 2016 Jan; 278(1):104-13. PubMed ID: 26200601
[TBL] [Abstract][Full Text] [Related]
7. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging.
Yabuuchi H; Hatakenaka M; Takayama K; Matsuo Y; Sunami S; Kamitani T; Jinnouchi M; Sakai S; Nakanishi Y; Honda H
Radiology; 2011 Nov; 261(2):598-604. PubMed ID: 21852569
[TBL] [Abstract][Full Text] [Related]
8. Rat model of reperfused partial liver infarction: characterization with multiparametric magnetic resonance imaging, microangiography, and histomorphology.
Wu X; Wang H; Chen F; Jin L; Li J; Feng Y; DeKeyzer F; Yu J; Marchal G; Ni Y
Acta Radiol; 2009 Apr; 50(3):276-87. PubMed ID: 19160078
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions.
Sun X; Wang H; Chen F; De Keyzer F; Yu J; Jiang Y; Feng Y; Li J; Marchal G; Ni Y
J Magn Reson Imaging; 2009 Mar; 29(3):621-8. PubMed ID: 19243058
[TBL] [Abstract][Full Text] [Related]
10. Normal and transplanted rat kidneys: diffusion MR imaging at 7 T.
Yang D; Ye Q; Williams DS; Hitchens TK; Ho C
Radiology; 2004 Jun; 231(3):702-9. PubMed ID: 15163810
[TBL] [Abstract][Full Text] [Related]
11. Role of diffusion-weighted magnetic resonance imaging in differentiation between the viable and necrotic parts of head and neck tumors.
Razek AA; Megahed AS; Denewer A; Motamed A; Tawfik A; Nada N
Acta Radiol; 2008 Apr; 49(3):364-70. PubMed ID: 18365828
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
13. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T.
Dong Y; Liu Q
J Comput Assist Tomogr; 2012; 36(4):361-6. PubMed ID: 22805661
[TBL] [Abstract][Full Text] [Related]
15. Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging.
Jugé L; Doan BT; Seguin J; Albuquerque M; Larrat B; Mignet N; Chabot GG; Scherman D; Paradis V; Vilgrain V; Van Beers BE; Sinkus R
Radiology; 2012 Aug; 264(2):436-44. PubMed ID: 22692038
[TBL] [Abstract][Full Text] [Related]
16. Parotid gland tumors: can addition of diffusion-weighted MR imaging to dynamic contrast-enhanced MR imaging improve diagnostic accuracy in characterization?
Yabuuchi H; Matsuo Y; Kamitani T; Setoguchi T; Okafuji T; Soeda H; Sakai S; Hatakenaka M; Nakashima T; Oda Y; Honda H
Radiology; 2008 Dec; 249(3):909-16. PubMed ID: 18941162
[TBL] [Abstract][Full Text] [Related]
17. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.
Buijs M; Kamel IR; Vossen JA; Georgiades CS; Hong K; Geschwind JF
J Vasc Interv Radiol; 2007 Aug; 18(8):957-63. PubMed ID: 17675611
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas.
Dudeck O; Zeile M; Pink D; Pech M; Tunn PU; Reichardt P; Ludwig WD; Hamm B
J Magn Reson Imaging; 2008 May; 27(5):1109-13. PubMed ID: 18425832
[TBL] [Abstract][Full Text] [Related]
19. Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade.
Kang Y; Choi SH; Kim YJ; Kim KG; Sohn CH; Kim JH; Yun TJ; Chang KH
Radiology; 2011 Dec; 261(3):882-90. PubMed ID: 21969667
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose.
Manka C; Träber F; Gieseke J; Schild HH; Kuhl CK
Radiology; 2005 Mar; 234(3):869-77. PubMed ID: 15665227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
